Company news: BMS, Novartis

Share this article:

The patents may be over, but the rights for Plavix and Avapro are still worthy of a deal. The latest deal is that BMS is letting Sanofi have the rights to Plavix back, except for the US and Puerto Rico. The deal gives BMS a royalty cut on branded and unbranded Plavix sales worldwide (except for the US) as well as on branded and unbranded Avapro sales worldwide.

Novartis presented data from its global EDGE study that the company said shows that "a significantly higher proportion" of type 2 diabetes patients responded to treatment with Galvus (vildagliptin), along with existing oral anti-diabetes therapy, or Eucreas (vildagliptin plus metformin), compared to combos of other oral anti-diabetes treatments. The data showed a 1.9% reduction in HbA1c when vildagliptin was added to existing oral anti-diabetes therapies.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.